Secukinumab sustains good efficacy and favourable safety in moderate-to-severe psoriasis after up to 3 years of treatment: results from a double-blind extension study.
Robert BissonnetteT LugerD ThaçiD TothI MessinaR YouA GuanaT FoxC PapavassilisI GilloteauU MrowietzPublished in: The British journal of dermatology (2017)
Secukinumab 300 mg FI sustained high responses and improved quality of life with no new safety concerns through 3 years.